Pompe Program Update from Genzyme
Posted on: March 02, 2009 - Filed under Pompe Program Update
Supply Update
In January 2009, Genzyme notified the Pompe community that we were experiencing a temporary constraint in the global supply of Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale and that inventories were extremely tight. We are pleased to inform you that the European Commission has approved the larger 4000 L scale production of Myozyme at Genzyme’s manufacturing facility in Belgium for use within the European Union. With this approval, the demand on the 2000 L inventories that currently supply the rest of the world, including MTAP in the US, has been relieved and the supply constraint is now resolved. The larger- scale Belgium facility will be able to help meet the long-term needs of patients for Myozyme upon receipt of approval by regulatory agencies throughout the world.
